China suspends Bristol-Myers' cancer drug over findings at U.S. plant

This post was originally published on this site

The suspension by China National Medical Products Administration is based on inspection findings at Bristol-Myers’ contract manufacturing facility in the United States, partner Beigene Ltd said.

Beigene and Bristol-Myers were working to restore supply as soon as possible, said the China-based drugmaker, which signed an agreement with Bristol-Myers’ Celgene (NASDAQ:CELG) unit in 2017 to market and distribute Abraxane.

Along with remediation efforts, Bristol-Myers has applied for approval to source its supply of Abraxane for the China market from an alternative manufacturing facility, Beigene said.